{"address1": "20 William Street", "address2": "Suite 145", "city": "Wellesley Hills", "state": "MA", "zip": "02481", "country": "United States", "phone": "866 857 2596", "website": "https://climbbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN). The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.", "fullTimeEmployees": 17, "companyOfficers": [{"maxAge": 1, "name": "Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc", "age": 48, "title": "CEO, President & Director", "yearBorn": 1976, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Brett  Kaplan M.B.A., M.D.", "age": 49, "title": "COO & Principal Financial Officer", "yearBorn": 1975, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Emily  Pimblett CPA", "age": 39, "title": "Senior VP of Finance & Chief Accounting Officer", "yearBorn": 1985, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nishi  Rampal M.D.", "title": "Senior Vice President of Clinical Development", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Janaki M. Subramanyam M.Sc.", "title": "VP & Head of Regulatory Affairs", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kate  Hecht M.B.A.", "title": "Senior Vice President of Program Management", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Perrin  Wilson B.S., Ph.D.", "title": "Chief Business Officer", "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1743465600, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.22, "open": 1.22, "dayLow": 1.2, "dayHigh": 1.31, "regularMarketPreviousClose": 1.22, "regularMarketOpen": 1.22, "regularMarketDayLow": 1.2, "regularMarketDayHigh": 1.31, "payoutRatio": 0.0, "beta": -0.185, "volume": 273359, "regularMarketVolume": 273359, "averageVolume": 357025, "averageVolume10days": 143350, "averageDailyVolume10Day": 143350, "bid": 1.19, "ask": 1.26, "bidSize": 1, "askSize": 1, "marketCap": 80970480, "fiftyTwoWeekLow": 1.2, "fiftyTwoWeekHigh": 11.55, "fiftyDayAverage": 1.5234, "twoHundredDayAverage": 4.343075, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -69416528, "profitMargins": 0.0, "floatShares": 30643276, "sharesOutstanding": 67475400, "sharesShort": 2192464, "sharesShortPriorMonth": 1898020, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0326, "heldPercentInsiders": 0.10146, "heldPercentInstitutions": 0.86116, "shortRatio": 6.35, "shortPercentOfFloat": 0.045, "impliedSharesOutstanding": 67475400, "bookValue": 3.15, "priceToBook": 0.3809524, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -73897000, "trailingEps": -1.53, "52WeekChange": -0.566787, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 1.2, "targetHighPrice": 10.0, "targetLowPrice": 10.0, "targetMeanPrice": 10.0, "targetMedianPrice": 10.0, "recommendationMean": 1.0, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 1, "totalCash": 150919008, "totalCashPerShare": 2.237, "totalDebt": 532000, "quickRatio": 30.833, "currentRatio": 31.408, "debtToEquity": 0.251, "returnOnAssets": -0.10302, "returnOnEquity": -0.46261, "freeCashflow": -9540875, "operatingCashflow": -15562000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "CLYM", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Climb Bio, Inc.", "regularMarketChange": -0.01999998, "regularMarketDayRange": "1.2 - 1.31", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 357025, "fiftyTwoWeekLowChange": 0.0, "fiftyTwoWeekLowChangePercent": 0.0, "fiftyTwoWeekRange": "1.2 - 11.55", "fiftyTwoWeekHighChange": -10.35, "fiftyTwoWeekHighChangePercent": -0.8961039, "fiftyTwoWeekChangePercent": -56.6787, "epsTrailingTwelveMonths": -1.53, "fiftyDayAverageChange": -0.3233999, "fiftyDayAverageChangePercent": -0.21228825, "twoHundredDayAverageChange": -3.1430748, "twoHundredDayAverageChangePercent": -0.723698, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Eliem Therapeutics, Inc.", "nameChangeDate": "2025-04-01", "averageAnalystRating": "1.0 - Strong Buy", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1628602200000, "longName": "Climb Bio, Inc.", "corporateActions": [], "regularMarketTime": 1743537602, "exchange": "NGM", "messageBoardId": "finmb_603195850", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "cryptoTradeable": false, "regularMarketChangePercent": -1.6393427, "regularMarketPrice": 1.2, "marketState": "PRE", "displayName": "Climb Bio", "trailingPegRatio": null}